Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome.

@article{Tan2004SomatostatinIL,
  title={Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome.},
  author={Tricia M. M. Tan and Mark Vanderpump and Bernard Khoo and Mike Patterson and Mohammad A. Ghatei and Anthony P. Goldstone},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2004},
  volume={89 8},
  pages={4162-5}
}
Prader-Willi syndrome (PWS) is characterized by life-threatening childhood-onset hyperphagia, obesity and, uniquely, high plasma levels of ghrelin, the orexigenic gastric hormone. Somatostatin suppresses ghrelin secretion in normal subjects. We therefore examined the effect of somatostatin on plasma ghrelin and appetite in four male PWS adults fasted overnight in a double-blind, placebo-controlled, randomized cross-over study. Subjects received an intravenous infusion of somatostatin (250… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Obesity management in Prader–Willi syndrome: current perspectives

Diabetes, metabolic syndrome and obesity : targets and therapy • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…